Salud financiera de hoja de balance de HLS Therapeutics
Salud financiera controles de criterios 3/6
HLS Therapeutics tiene un patrimonio de los accionistas total de $79.3M y una deuda total de $67.8M, lo que sitúa su ratio deuda-patrimonio en 85.4%. Sus activos y pasivos totales son $171.7M y $92.4M respectivamente.
Información clave
85.4%
Ratio deuda-patrimonio
US$67.78m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$17.54m |
| Patrimonio | US$79.33m |
| Total pasivo | US$92.41m |
| Activos totales | US$171.74m |
Actualizaciones recientes sobre salud financiera
Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Apr 06
Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Sep 13Would HLS Therapeutics (TSE:HLS) Be Better Off With Less Debt?
May 05We Think HLS Therapeutics (TSE:HLS) Has A Fair Chunk Of Debt
Sep 14Recent updates
Are Investors Undervaluing HLS Therapeutics Inc. (TSE:HLS) By 45%?
Oct 26Pinning Down HLS Therapeutics Inc.'s (TSE:HLS) P/S Is Difficult Right Now
Sep 28Analysts Have Lowered Expectations For HLS Therapeutics Inc. (TSE:HLS) After Its Latest Results
May 12After Leaping 29% HLS Therapeutics Inc. (TSE:HLS) Shares Are Not Flying Under The Radar
Apr 14Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Apr 06Analysts Are More Bearish On HLS Therapeutics Inc. (TSE:HLS) Than They Used To Be
Nov 16Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Sep 13Would HLS Therapeutics (TSE:HLS) Be Better Off With Less Debt?
May 05HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Apr 05HLS Therapeutics (TSE:HLS) Is Paying Out A Dividend Of $0.05
Mar 20HLS Therapeutics (TSE:HLS) Has Affirmed Its Dividend Of $0.05
Nov 30Downgrade: Here's How Analysts See HLS Therapeutics Inc. (TSE:HLS) Performing In The Near Term
Nov 11We Think HLS Therapeutics (TSE:HLS) Has A Fair Chunk Of Debt
Sep 14HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Aug 15HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Jul 14HLS Therapeutics (TSE:HLS) Has Announced A Dividend Of CA$0.05
Jun 23HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
Jun 08HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
May 25HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
May 10Time To Worry? Analysts Are Downgrading Their HLS Therapeutics Inc. (TSE:HLS) Outlook
Apr 30HLS Therapeutics (TSE:HLS) Has Affirmed Its Dividend Of CA$0.05
Apr 15HLS Therapeutics (TSE:HLS) Has Re-Affirmed Its Dividend Of CA$0.05
Mar 26HLS Therapeutics Inc. (TSE:HLS) Analysts Just Slashed This Year's Estimates
Mar 22Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($37.6M) de HLS superan a sus pasivos a corto plazo ($24.1M).
Pasivo a largo plazo: Los activos a corto plazo ($37.6M) de HLS no cubren sus pasivos a largo plazo ($68.3M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: La relación deuda neta-capital de HLS (63.3%) se considera alta.
Reducción de la deuda: El ratio deuda-patrimonio de HLS ha crecido de 50.7% a 85.4% en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: Aunque no es rentable HLS tiene suficiente cash runway para más de 3 años si mantiene su actual nivel positivo de flujo de caja libre.
Pronóstico de cash runway: HLS no es rentable pero tiene suficiente cash runway para más de 3 años, debido a que el flujo de caja libre es positivo y crece un 6.2% al año.